Leronlimab Biosimilar - Research Grade

Human

CCR5

>1mg/ml

IgG4 - kappa

CHO Cells

Bulk Anti-Human CD195 (HEK/1/85a/7a) Antibody (CCR5) (ICH1172)

https://www.imgt.org/mAb-DB/

ICH3002

P51681

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-CCR5 antibody leronlimab (PRO 140), supplied for research use only and not for human or veterinary use. Built as a human IgG4-kappa targeting human CCR5 (UniProt P51681), it lets laboratories reproduce the binding and receptor-blocking behavior associated with the originator molecule in a bench setting rather than a clinical one. Typical research applications include use as a reference or positive-control reagent in CCR5 binding and competition assays, as a tool for probing CCR5-dependent HIV-1 entry and chemokine signaling in vitro, and as a benchmarking standard when developing or characterizing new anti-CCR5 biologics. It is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), and can be produced in bulk milligram-to-gram quantities to support assay development, formulation work, and preclinical experimentation. Because it is an analog rather than the clinical drug, it should be validated in the user's own system before use. CCR5 (C-C chemokine receptor type 5; UniProt P51681) is a seven-transmembrane G-protein-coupled receptor expressed mainly on T cells, macrophages, dendritic cells, and microglia. Its natural ligands are the inflammatory CC-chemokines CCL3 (MIP-1-alpha), CCL4 (MIP-1-beta), and CCL5 (RANTES), and engagement drives Gi-coupled signaling, calcium flux, and directed leukocyte migration to sites of inflammation. CCR5 is best known as the principal co-receptor, alongside CD4, that R5-tropic HIV-1 uses to enter host cells; the homozygous CCR5-delta32 loss-of-function variant confers substantial resistance to HIV-1 infection. Beyond HIV, CCR5 signaling contributes to inflammatory and immune trafficking and has been studied in transplantation, graft-versus-host disease, and certain cancers. Antibodies or small molecules that occupy CCR5 can block both chemokine-driven signaling and viral co-receptor function.

C-C chemokine receptor type 5, CC-CKR-5, CCR-5, CHEMR13, HIV-1 fusion coreceptor, CD195

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Leronlimab biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Leronlimab biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Leronlimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Leronlimab that binds CCR5; for research use only.